Warning! GuruFocus detected
1 Severe warning sign
with ONCT.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Oncternal Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US40052B2079
Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 76.33 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 6.4 | |||||
| 3-Year EPS without NRI Growth Rate | 7.6 | |||||
| 3-Year FCF Growth Rate | 14.1 | |||||
| 3-Year Book Growth Rate | -39.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.36 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 18.65 | |||||
| 14-Day RSI | 25.19 | |||||
| 6-1 Month Momentum % | -57.87 | |||||
| 12-1 Month Momentum % | -94.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | |||||
| Quick Ratio | 2.39 | |||||
| Cash Ratio | 2.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 2.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -150.49 | |||||
| ROA % | -116.39 | |||||
| ROIC % | -1164.85 | |||||
| 3-Year ROIIC % | 1515.49 | |||||
| ROC (Joel Greenblatt) % | -16081.84 | |||||
| ROCE % | -152.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.17 | |||||
| Price-to-Tangible-Book | 0.17 | |||||
| EV-to-EBIT | 0.36 | |||||
| EV-to-EBITDA | 0.36 | |||||
| EV-to-Forward-Revenue | 0.51 | |||||
| EV-to-FCF | 0.48 | |||||
| Price-to-Net-Current-Asset-Value | 0.17 | |||||
| Price-to-Net-Cash | 0.19 | |||||
| Earnings Yield (Greenblatt) % | 277.78 | |||||
| FCF Yield % | -1708.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ONCT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncternal Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -11.69 | ||
| Beta | 0.83 | ||
| 3-Year Sharpe Ratio | -0.93 | ||
| 3-Year Sortino Ratio | -1.11 | ||
| Volatility % | 85.63 | ||
| 14-Day RSI | 25.19 | ||
| 14-Day ATR ($) | 0.000364 | ||
| 20-Day SMA ($) | 0.5266 | ||
| 12-1 Month Momentum % | -94.15 | ||
| 52-Week Range ($) | 0.5266 - 9.88 | ||
| Shares Outstanding (Mil) | 2.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncternal Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncternal Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncternal Therapeutics Inc Frequently Asked Questions
What is Oncternal Therapeutics Inc(ONCT)'s stock price today?
The current price of ONCT is $0.53. The 52 week high of ONCT is $9.88 and 52 week low is $0.53.
When is next earnings date of Oncternal Therapeutics Inc(ONCT)?
The next earnings date of Oncternal Therapeutics Inc(ONCT) is 2025-04-04 Est..
Does Oncternal Therapeutics Inc(ONCT) pay dividends? If so, how much?
Oncternal Therapeutics Inc(ONCT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers